Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.
Dato-DXd Does Not Elicit Significant OS Improvement in Previously Treated, Advanced NSCLC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC
When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies